Drug Patents owned by Array Biopharma Inc
1. Drug name - BRAFTOVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8946250 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Jul, 2029
(6 years from now) | |
| US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(7 years from now) | |
| US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Mar, 2031
(8 years from now) | |
| CN102105459A | ARRAY BIOPHARMA INC | 3,4-Diarylpyrazoles As Protein Kinase Inhibitors |
Jul, 2029
(6 years from now) | |
| CN102105459B | ARRAY BIOPHARMA INC | 3,4-Diarylpyrazoles As Protein Kinase Inhibitors |
Jul, 2029
(6 years from now) | |
| CN102725283B | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| CN102725283A | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| CN103896921A | ARRAY BIOPHARMA INC | Compound And Composition As A Protein Kinase Inhibitor |
Aug, 2030
(7 years from now) | |
| CN103896921B | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| IN201202469P1 | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| IN303554B | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| EP2324008B1 | ARRAY BIOPHARMA INC | 3,4-Diarylpyrazoles As Protein Kinase Inhibitors |
Jul, 2029
(6 years from now) | |
| EP2324008A1 | ARRAY BIOPHARMA INC | 3,4-Diarylpyrazoles As Protein Kinase Inhibitors |
Jul, 2029
(6 years from now) | |
| EP2727918A1 | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| EP2470526B1 | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| EP2727918B1 | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| EP2470526A1 | ARRAY BIOPHARMA INC | Compounds And Compositions As Protein Kinase Inhibitors |
Aug, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(8 years from now) | |
| US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(10 years from now) | |
| US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(10 years from now) | |
| US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(10 years from now) | |
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(10 years from now) | |
Drugs and Companies using ENCORAFENIB ingredient
Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | CAPSULE;ORAL | Discontinued |
| 75MG | CAPSULE;ORAL | Prescription |
2. Drug name - MEKTOVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8178693 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(5 months from now) | |
| US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(5 months from now) | |
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(11 years from now) | |
| CN1874768A | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Jan, 2010
(12 years ago) | |
| CN101633644B | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN100519539C | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN101633645B | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN101486682A | ARRAY BIOPHARMA INC | N3 Alkylated Benzoimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN101486682B | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN1652776A | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| CN101633645A | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor |
Mar, 2023
(5 months from now) | |
| CN101633644A | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivative Used As Mek Inhibitor |
Mar, 2023
(5 months from now) | |
| CN104870427B | ARRAY BIOPHARMA INC | Preparation And Formulation Comprising An Mek Inhibitor Of Mek Inhibitors |
Oct, 2033
(11 years from now) | |
| CN104870427A | ARRAY BIOPHARMA INC | Preparation Of Formulation Comprising Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| IN200403046P1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| IN248684B | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| IN201501287P2 | ARRAY BIOPHARMA INC | Preparation Of And Formulation Comprising A Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| IN334786B | ARRAY BIOPHARMA INC | Preparation Of And Formulation Comprising A Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| EP2130537B1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP2130536B1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP3000810B1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivative As Mek Inhibitor |
Mar, 2023
(5 months from now) | |
| EP2130536A1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP2275102B1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP3000810A1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivative As Mek Inhibitor |
Mar, 2023
(5 months from now) | |
| EP2130537A1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP2275102A1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP1482932A4 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP1482932A1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP1482932B1 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Mar, 2023
(5 months from now) | |
| EP1663210A1 | ARRAY BIOPHARMA INC | Benzimidazole Derivatives As Mek Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP1663210B1 | ARRAY BIOPHARMA INC | Benzimidazole Derivatives As Mek Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP1663210A4 | ARRAY BIOPHARMA INC | N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP2909182A1 | ARRAY BIOPHARMA INC | Preparation Of And Formulation Comprising A Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| EP2909182B1 | ARRAY BIOPHARMA INC | Preparation Of And Formulation Comprising A Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| EP2909182A4 | ARRAY BIOPHARMA INC | Preparation Of And Formulation Comprising A Mek Inhibitor |
Oct, 2033
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8193229 | ARRAY BIOPHARMA INC | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(5 months from now) | |
| US8513293 | ARRAY BIOPHARMA INC | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar, 2023
(5 months from now) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(8 years from now) | |
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(11 years from now) | |
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(11 years from now) | |
Drugs and Companies using BINIMETINIB ingredient
Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase; Treatment of melanoma with a braf mutation
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.